BIIB 513
Latest Information Update: 29 Jan 2003
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Medical College of Wisconsin
- Class Anti-ischaemics; Mesylates; Small molecules
- Mechanism of Action Sodium-hydrogen antiporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 29 Jan 2003 No development reported - Preclinical for Ischaemic heart disorders in Germany (unspecified route)
- 29 Jan 2003 No development reported - Preclinical for Ischaemic heart disorders in USA (unspecified route)
- 15 Mar 2001 Preclinical development for Ischaemic heart disorders in USA (Unknown route)